Linked Life Data

18508296

Source:http://linkedlifedata.com/resource/pubmed/id/18508296

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-6-3
pubmed:databankReference
pubmed:abstractText
Recommended treatment for hepatitis C virus genotype 1 (HCV-1) patients is peginterferon plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as effective as standard treatment in HCV-1 patients with a rapid virological response (RVR; seronegative for hepatitis C virus [HCV] RNA at 4 weeks). Two hundred HCV-1 patients were randomized (1:1) to either 24 or 48 weeks of peginterferon-alpha-2a (180 microg/week) and ribavirin (1000-1200 mg/day) with a 24-week follow-up. The primary endpoint was a sustained virological response (SVR; seronegative for HCV RNA at 24-week follow-up). Overall, the 48-week arm had a significantly higher SVR rate (79%) than the 24-week arm (59%, P = 0.002). For 87 (43.5%) patients with an RVR, the 24-week arm had a lower SVR rate [88.9%; 95% confidence interval (CI): 80%-98%] than the 48-week arm (100%, P = 0.056). For 52 patients with low baseline viremia (<400,000 IU/mL) and an RVR, the 24-week arm had rates (CI) of relapse and SVR of 3.6% (-3%-11%) and 96.4% (89%-103%), respectively, which were comparable to those of the 48-week arm (0% and 100%) with difference (CI) of 3.6% (-7.2%-6.6%) and -3.6% (-14.3% to -0.6%), respectively. Multivariate analysis in all patients showed that RVR was the strongest independent factor associated with an SVR, followed by treatment duration, mean weight-based exposure of ribavirin, and baseline viral load. CONCLUSION: HCV-1 patients derive a significantly better SVR from 48 weeks versus 24 weeks of peginterferon/ribavirin even if they attain an RVR. Both 24 and 48 weeks of therapy can achieve high SVR rates (>96%) in HCV-1 patients with low viral loads and an RVR.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1527-3350
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1884-93
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:18508296-Adult, pubmed-meshheading:18508296-Antiviral Agents, pubmed-meshheading:18508296-Dose-Response Relationship, Drug, pubmed-meshheading:18508296-Drug Therapy, Combination, pubmed-meshheading:18508296-Female, pubmed-meshheading:18508296-Follow-Up Studies, pubmed-meshheading:18508296-Genotype, pubmed-meshheading:18508296-Hepacivirus, pubmed-meshheading:18508296-Hepatitis C, Chronic, pubmed-meshheading:18508296-Humans, pubmed-meshheading:18508296-Interferon-alpha, pubmed-meshheading:18508296-Male, pubmed-meshheading:18508296-Middle Aged, pubmed-meshheading:18508296-Multivariate Analysis, pubmed-meshheading:18508296-Polyethylene Glycols, pubmed-meshheading:18508296-Prospective Studies, pubmed-meshheading:18508296-RNA, Viral, pubmed-meshheading:18508296-Recombinant Proteins, pubmed-meshheading:18508296-Ribavirin, pubmed-meshheading:18508296-Time Factors, pubmed-meshheading:18508296-Treatment Outcome, pubmed-meshheading:18508296-Viral Load, pubmed-meshheading:18508296-Viremia
pubmed:year
2008
pubmed:articleTitle
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
pubmed:affiliation
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study